Pain treatment biotech Egalet files for a $69 million IPO
Egalet, which is developing abuse-deterrent oral products for the treatment of pain, filed on Wednesday with the SEC to raise up to $69 million in an initial public offering. The Malvern, PA-based company, which was founded in 1995, plans to list on the NASDAQ under the symbol EGLT. Egalet initially filed confidentially on September 17, 2013. Stifel and JMP Securities are the joint bookrunners on the deal. No pricing terms were disclosed.